1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Alberto Abaterusso
Alberto Abaterusso
Articles (2392) 

Amgen Files Marketing Applications to Expand Xgeva's Use to US and EU MM Paitents

XGEVA would be commercialized as a therapy to prevent skeletal-related events

April 09, 2017 | About:

Amgen Inc. (NASDAQ:AMGN) announced to the markets last Tuesday, April 4, that it has filed with the U.S. FDA a supplemental Biologics License Application and with the European Medicines Agency an application for a variation to its MAA, seeking the inclusion of multiple myeloma patients in the Xgeva’s (denosumab) label, in order to prevent these patients from developing skeletal-related problems as a complication of plasma cells cancer.

Xgeva is currently approved for the prevention of skeletal-related events in patients affected with solid tumours. These solid tumours’ complications include fractures, spinal cord compression and others that make it necessary to resort to radiotherapy or surgery.

The company said that “the applications include new data from the pivotal Phase 3 head-to-head 482 study, the largest international multiple myeloma trial ever conducted."

Xgeva is the brand name under which denosumab is commercialized. Denosumab is a monoclonal antibody (a type of protein) designed to bind to an antigen called RANKL which is implicated in the activation of osteoclasts, the cells of the organism that plays a role in the degradation of bone tissue. Denosumab reduces the formation and activity of osteoclasts, by binding to the antigen and inhibiting its action. This in turn limits the loss of bone, making fractures and other serious complications of the skeletal system less likely.

In 2016, revenue from the sale of Xgeva was $1.59 billion, a 9% increase year over year. Approximately 73% of Amgen’s Xgeva sales came from the U.S. and 27% from the rest of the world.

April 7, Amgen closed at $163.38, up $1.13 or 0.70% from the previous trading day, with a volume of 1,973,170 shares traded on the NasdaqGS versus an average volume of 2.9 million shares traded over the last 10 trading days and an average volume of 3.92 million shares traded over the last three months.

The health care stock has been trading down since mid-March; however, it gained 8% year to date and it is more volatile than the stock market with a beta of 1.78.

Amgen closed the last trading days of week 14 with a price-sales ratio of 5.23 and a price-book ratio of 4.04. The trailing price-earnings ratio is 15.96. Considering that the forward price-earnings ratio is 12.85 and for 2017 analysts forecast EPS of $12.31 on average (5.7% growth from 2016), the stock seems to be overvalued by the stock market at the moment. However, for the majority of analysts, Amgen is a buy with a recommendation rating of 2.4 and an average target price of $185.50 per share.

Disclosure: I have no position in Amgen Inc.

About the author:

Alberto Abaterusso
I am a contributor at GuruFocus. I primarily write about how to pick potential value stocks. Gold, silver and precious metals mining industries is also my cup of tea. My articles have also been widely linked by popular sites, including MarketWatch, Financial Times, 24hGold, Investopedia, Financial.org, CNBS, MSN Money, Zachs, Reuters and others. I hold a Master\\\'s Degree in Business Administration from Università degli Studi di Bari (Italy), Aldo Moro. I am based in The Netherlands.

You can follow me on Twitter at https://twitter.com/AAbaterusso

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by Alberto Abaterusso


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)